Abstract
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that plays a critical role in diverse cellular functions, such as DNA damage detection and repair, transcriptional regulation and cell death. Furthermore, PARP-1 has emerged as a key player in the pathogenesis of multiple inflammatory diseases and has become a promising target for the treatment of cardiovascular disorders, neurodegenerative diseases and cancer. An increasing body of evidence has linked alterations in the expression levels of PARP-1, enzymatic activity and presence of polymorphism to gastrointestinal malignancies, including oesophageal, gastric, pancreas, liver and colorectal cancers. PARP inhibition has been proposed as a valuable strategy for treating these gastrointestinal disorders. This paper summarises the most significant current literature on the involvement of PARP-1 in gastrointestinal cancer, focusing in particular on its role in the development and occurrence of tumours, providing information about clinical trials and exploring therapeutic possibilities.
Keywords: Biomarker, carcinogenesis, gastrointestinal cancer, PARP inhibitors, poly (ADP-ribose) polymerase-1 (PARP-1), synthetic lethality.
Current Medicinal Chemistry
Title:Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement
Volume: 24 Issue: 20
Author(s): Sandra M. Martín-Guerrero, Josefa León, Rosa Quiles-Perez, Laura Belmonte, David Martin-Oliva, Ángeles Ruiz-Extremera, Javier Salmerón and José Antonio Muñoz-Gámez*
Affiliation:
- Laboratory of Medical Research, Clinical Management Unit of Digestive Disease, San Cecilio University Hospital, Avda de Madrid s/n, 18012, Granada,Spain
Keywords: Biomarker, carcinogenesis, gastrointestinal cancer, PARP inhibitors, poly (ADP-ribose) polymerase-1 (PARP-1), synthetic lethality.
Abstract: Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that plays a critical role in diverse cellular functions, such as DNA damage detection and repair, transcriptional regulation and cell death. Furthermore, PARP-1 has emerged as a key player in the pathogenesis of multiple inflammatory diseases and has become a promising target for the treatment of cardiovascular disorders, neurodegenerative diseases and cancer. An increasing body of evidence has linked alterations in the expression levels of PARP-1, enzymatic activity and presence of polymorphism to gastrointestinal malignancies, including oesophageal, gastric, pancreas, liver and colorectal cancers. PARP inhibition has been proposed as a valuable strategy for treating these gastrointestinal disorders. This paper summarises the most significant current literature on the involvement of PARP-1 in gastrointestinal cancer, focusing in particular on its role in the development and occurrence of tumours, providing information about clinical trials and exploring therapeutic possibilities.
Export Options
About this article
Cite this article as:
Martín-Guerrero M. Sandra, León Josefa , Quiles-Perez Rosa , Belmonte Laura, Martin-Oliva David , Ruiz-Extremera Ángeles, Salmerón Javier and Muñoz-Gámez Antonio José *, Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement, Current Medicinal Chemistry 2017; 24 (20) . https://dx.doi.org/10.2174/0929867324666170316115039
DOI https://dx.doi.org/10.2174/0929867324666170316115039 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Realizing the Potential of Blueberry as Natural Inhibitor of Metastasis and Powerful Apoptosis Inducer: Tapping the Treasure Trove for Effective Regulation of Cell Signaling Pathways
Anti-Cancer Agents in Medicinal Chemistry Cell Cycle Regulatory Kinase Modulators: Interim Progress and Issues
Current Topics in Medicinal Chemistry Carbonic Anhydrase Inhibitors and the Management of Cancer
Current Topics in Medicinal Chemistry Safety and Proof-of-Concept Efficacy of Inhaled Drug Loaded Nano- and Immunonanoparticles in a c-Raf Transgenic Lung Cancer Model
Current Cancer Drug Targets Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells
Current Medicinal Chemistry Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Genetics of Obesity: What have we Learned?
Current Genomics Probiotic Research in Australia, New Zealand and the Asia-Pacific Region
Current Pharmaceutical Design Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Last Advances in Nanocarriers-Based Drug Delivery Systems for Colorectal Cancer
Current Drug Delivery Electron Paramagnetic Resonance (EPR) Spectroscopy: A Versatile and Powerful Tool in Pharmaceutical and Biomedical Analysis
Current Pharmaceutical Analysis Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Evidences and Opinions for Adjuvant Therapy in Pancreatic Cancer
Current Drug Targets Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry Editorial (thematic Issue: Functional Performance of L-Carnosine (β-Alanyl-L-Histidine) and Related Imidazole-Containing Dipeptides. Design and Modern Applications of Drug Delivery Systems (Nanosuspensions of Nanosize Materials, Mucoadhesive Drug Delivery Systems, Formulations of Transdermal Patches for Controlled Drug Delivery)
Recent Patents on Drug Delivery & Formulation 3-(4-Geranyloxy-3-Methoxyphenyl)-2-trans Propenoic Acid: A Novel Promising Cancer Chemopreventive Agent
Anti-Cancer Agents in Medicinal Chemistry Calix[n]arenes as Goldmines for the Development of Chemical Entities of Pharmaceutical Interest
Current Pharmaceutical Design Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Molecule of the Month
Current Topics in Medicinal Chemistry